

CMP: ₹ 252

Target: ₹ 320(27%)

Target Period: 12 months

BUY

December 24, 2024

CDMO growth momentum likely to persist...

About the stock: Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates in 3 major segments.

- Contract development and manufacturing organisations (CDMO)
- Complex hospital generics (critical care)
- Consumer healthcare (OTC).

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with Allergan, and 33.33% in Yapan Bio which operates in the biologics / bio-therapeutics and vaccine segments.

Investment Rationale:

- Q2FY25 results- CDMO continues to provide strong momentum- Revenues grew ~17% YoY to ₹ 2242 crore on the back of ~24% growth in the CDMO business (59% of sales) to ₹ 1324. Complex Hospitals Generics (29% of sales) on the other hand grew 9% to ₹ 643 crore and India Consumer Business (12% of sales) grew ~8% to ₹ 277 crore. EBITDA grew ~29% YoY to ₹ 342 crore with 134 bps margin expansion to 15.2% driven by better operating leverage and despite 216 bps de-growth in GPM.
- CDMO business was driven by order inflows, especially for on-patent commercial manufacturing. The company also witnessed good demand for differentiated offerings with increase in customer enquiries and visits. In India Consumer Business, growth was driven by new launches and 18% growth in power brands. In Complex Hospitals Generics, the growth was driven by volume growth in inhalation anaesthesia portfolio in the US and emerging markets.
- Biosecure Act enactment postponed, but other growth levers intact- Despite likely delay in the enactment of US Biosecure Act for want of passage in the US Senate, we do not see growth related issues as the China rebalancing drive (which was started way before the Biosecure build-up) by global innovators is likely to continue. Other levers such as global consolidation in the CDMO space, improving US biotech funding and extended focus on some of the blockbuster themes (GLP-1, ADCs) are likely to maintain the orderbook momentum. The guidance for FY30E for US\$ 2 billion revenues and around 25% EBITDA margins is irrespective of the positive implications of the Biosecure Act and hence provide better visibility. We roll forwards our estimates by introducing FY27E.

Rating and Target price

We now value PPL at ₹ 320 based on SoTP valuations, i.e. 21x FY27E CDMO EBITDA, 17x FY27E CHG EBITDA, 1.5x FY27E Consumer Healthcare Sales (earlier 1x), and 10x PAT from AbbVie JV.




Particulars

Particular	Amount
Market Capitalisation	₹ 33338 crore
Debt (FY24)	₹ 4710 crore
Cash (FY24)	₹ 357 crore
EV	₹ 37692 crore
52 week H/L	308/114
Equity capital	₹ 1323 crore
Face value	₹ 10

Shareholding pattern

Particular	Dec-23	Mar-24	Jun-24	Sep-24
Promoters	35.0	35.0	34.9	34.9
FII's	32.5	30.6	31.4	31.7
DII's	9.7	12.1	13.0	13.8
Others	22.8	22.3	20.7	19.5

Price Chart



Key risks

- Higher sensitivity of CDMO business towards overall performance.
- Price Erosion and supply issues in CHG

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Shubh Mehta
shubh.mehta@icicisecurities.com

Vedant Nilekar
vedant.nilekar@icicisecurities.com

Key Financial Summary

(₹ Crore)	FY22	FY23	FY24	CAGR FY22-24 (%)	FY25E	FY26E	FY27E	CAGR FY24-26 (%)
Revenues	6559.1	7081.6	8171.2	12.4	9312.6	10575.7	11820.8	12.7
EBITDA	949.7	628.2	1196.3	13.0	1369.1	1830.9	2273.4	28.9
EBITDA Margins (%)	14.5	8.9	14.6		14.7	17.3	19.2	
Net Profit	376.0	-186.5	17.8	-41.6	75.0	457.4	746.5	215.5
Adjusted EPS (₹)	3.0	-1.4	0.6		0.6	3.5	5.7	
PE (x)	88.5	-178.4	1866.7		443.5	72.7	44.6	
EV/EBITDA (x)	39.1	60.9	31.3		27.6	20.2	15.9	
RoCE (%)	5.9	1.4	5.0		5.6	8.1	11.1	
RoE (%)	5.8	-2.7	1.0		0.9	5.5	8.2	

Exhibit 1: Quarterly Summary

(? crore)	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	YoY (%)	QoQ (%)
Net Sales	1577.5	1539.1	2131.4	1482.0	1720.0	1716.0	2163.6	1748.9	1911.4	1958.6	2552.4	1951.1	2241.8	17.3	14.9
Other Operating Income	1577.5	1539.1	2131.4	1482.0	1720.0	1716.0	2163.6	1748.9	1911.4	1958.6	2552.4	1951.1	2241.8	17.3	14.9
Variable Cost of Sales	606.0	547.4	840.0	574.3	663.9	625.3	839.7	626.7	637.7	675.2	1014.4	674.4	796.5	24.9	18.1
% of Revenue	38.4	35.6	39.4	38.8	38.6	36.4	38.8	35.8	33.4	34.5	39.7	34.6	35.5	216 bps	97 bps
Gross Profit	971.6	991.7	1291.3	907.7	1056.1	1090.7	1323.9	1122.1	1273.7	1283.4	1538.0	1276.8	1445.3	13.5	13.2
Gross Profit Margin (%)	61.6	64.4	60.6	61.2	61.4	63.6	61.2	64.2	66.6	65.5	60.3	65.4	64.5	-216 bps	-97 bps
Employee Expenses	400.0	396.2	402.9	460.5	470.1	492.2	473.5	495.5	516.0	523.8	494.2	579.7	559.5	8.4	-3.5
% of Revenue	25.4	25.7	18.9	31.1	27.3	28.7	21.9	28.3	27.0	26.7	19.4	29.7	25.0	-204 bps	-475 bps
Other Expenditure	375.0	370.0	490.5	430.0	413.5	511.1	499.1	494.3	492.0	491.3	513.9	492.6	544.1	10.6	10.5
% of Revenue	23.8	24.0	23.0	29.0	24.0	29.8	23.1	28.3	25.7	25.1	20.1	25.2	24.3	-147 bps	-97 bps
Total Operating Expendit	1381.0	1313.5	1733.4	1464.9	1547.5	1628.6	1812.3	1616.5	1645.7	1690.2	2022.4	1746.7	1900.1	15.5	8.8
% of Revenue	87.5	85.3	81.3	98.8	90.0	94.9	83.8	92.4	86.1	86.3	79.2	89.5	84.8	-134 bps	-476 bps
Operating Profit (EBITDA)	196.6	225.6	398.0	17.1	172.6	87.3	351.3	132.3	265.6	268.4	529.9	204.5	341.6	28.6	67.1
EBITDA Margin (%)	12.5	14.7	18.7	1.2	10.0	5.1	16.2	7.6	13.9	13.7	20.8	10.5	15.2	134 bps	476 bps
Depreciation	138.1	147.2	165.2	161.7	166.2	164.4	184.4	173.6	184.5	186.3	196.1	184.6	192.2	4.2	4.2
Interest	49.2	50.1	57.1	62.3	83.0	94.7	104.3	118.5	109.9	105.9	114.2	107.0	107.6	-2.0	0.6
Other Income	17.9	160.6	78.1	71.9	46.2	82.5	24.5	38.3	49.2	61.5	26.4	19.5	61.1	24.2	212.7
PBT	27.3	188.9	253.9	-135.0	-37.4	-89.2	87.1	-121.5	20.5	5.4	215.4	-67.5	102.9	403.0	-252.4
Total Tax	7.0	34.7	68.9	-6.1	11.1	16.5	44.8	-8.5	34.5	9.3	126.2	43.6	97.5	182.4	123.9
Tax rate (%)	25.8	18.4	27.1	4.5	-29.7	-18.5	51.4	7.0	168.9	171.0	58.6	-64.6	94.8	-7408 bps	15937 bps
PAT	36.6	163.4	204.1	-109.1	-37.3	-90.2	50.1	-98.6	5.0	10.1	101.3	-88.6	22.6	350.0	-125.5
PAT Margin (%)	2.3	10.6	9.6	-7.4	-2.2	-5.3	2.3	-5.6	0.3	0.5	4.0	-4.5	1.0	75 bps	555 bps

Source: Company, ICICI Direct Research

Exhibit 2: Valuation Summary

Particulars	FY27E (₹ cr)	Multiple (x)	EV (₹ cr)
CDMO EBITDA	1365.9	21.0	28,684
CHG EBITDA	828.3	17.0	14,081
Consumer Healthcare Sales	1318.7	1.5	1,978
AbbVie PAT(49%)	79.2	10	792
Net Debt FY27E (₹ cr)			2909.9
Targeted MCap (₹ cr)			42,625
No of shares (cr)			132.3
Per Share Value (₹)			320

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 3: Profit and loss statement				
	₹ crore			
(Year-end March)/(₹ crore)	FY24	FY25E	FY26E	FY27E
Total Operating Income	8,171.2	9,312.6	10,575.7	11,820.8
Growth (%)	15.4	14.0	13.6	11.8
Raw Material Expenses	1,976.8	1,865.3	1,692.1	1,891.3
Gross Profit	5,217.2	6,050.9	6,990.5	7,813.6
Gross Profit Margins (%)	63.8	65.0	66.1	66.1
Employee Expenses	2,029.5	2,265.0	2,448.4	2,736.6
Other Expenditure	1,991.4	2,416.8	2,711.2	2,803.6
Total Operating Expenditure	6,974.9	7,943.4	8,744.8	9,547.4
EBITDA	1,196.3	1,369.1	1,830.9	2,273.4
Growth (%)	90.4	14.5	33.7	24.2
Interest	448.5	446.7	415.8	367.3
Depreciation	740.6	793.1	882.1	916.1
Other Income	175.4	133.5	109.3	122.2
PBT before Exceptional Items	182.6	262.8	642.4	1,112.2
Less: Exceptional Items	62.8	0.0	0.0	0.0
PBT after Exceptional Items	119.8	262.8	642.4	1,112.2
Total Tax	161.5	253.2	256.9	444.9
PAT before MI	-41.7	9.6	385.4	667.3
PAT	17.8	75.0	457.4	746.5
Growth (%)	-109.6	320.9	509.9	63.2
EPS (Adjusted)	0.6	0.6	3.5	5.7
Other income as % of (Cash+inv	24%	26%	13%	11%

Source: Company, ICICI Direct Research

Exhibit 4: Cash flow statement				
	₹ crore			
(Year-end March)/(₹ crore)	FY24	FY25E	FY26E	FY27E
Profit/(Loss) after taxation	-37.0	75.0	457.4	746.5
Add: Depreciation & Amortizati	702.6	793.1	882.1	916.1
Net Increase in Current Assets	-880.4	-138.0	-967.3	-632.1
Net Increase in Current Liabilitie	646.1	-166.6	562.8	237.2
Others	573.3	446.7	415.8	367.3
CF from Operating activities	1,004.5	1,010.3	1,350.7	1,635.0
Investments	274.0	143.9	0.0	0.0
(Purchase)/Sale of Fixed Assets	-712.0	-775.4	-500.0	-500.0
Others	4.0	-18.4	400.7	2.8
CF from Investing activities	-434.0	-649.9	-99.3	-497.2
(inc)/Dec in Loan	-971.5	76.3	-500.0	-500.0
Dividend & Dividend tax	0.0	0.0	0.0	0.0
Other	549.2	-446.6	-415.8	-367.3
CF from Financing activities	-422.4	-370.3	-915.8	-867.3
Net Cash Flow	166.0	-86.5	335.6	270.6
Cash and Cash Equivalent	53.2	356.8	270.3	605.9
Cash	219.2	270.3	605.9	876.5
Free Cash Flow	292.5	234.9	850.7	1,135.0

Source: Company, ICICI Direct Research

Exhibit 5: Balance Sheet				
	₹ crore			
(Year-end March)	FY24	FY25E	FY26E	FY27E
Equity Capital	1,323.0	1,323.1	1,323.1	1,323.1
Reserve and Surplus	6,588.4	6,584.0	7,037.8	7,780.7
Total Shareholders funds	7,911.4	7,907.2	8,360.9	9,103.8
Total Debt	4,710.2	4,786.4	4,286.4	3,786.4
Deferred Tax Liability	229.2	233.3	238.0	242.8
Long-Term Provisions	32.3	41.9	42.7	43.6
Other Non Current Liabilities	167.9	178.6	182.2	185.8
Source of Funds	13,051	13,147	13,110	13,362
Gross Block - Fixed Assets	9,415.9	10,177.4	10,577.4	10,977.4
Accumulated Depreciation	2,548.5	3,341.6	4,223.7	5,139.8
Net Block	6,867.4	6,835.8	6,353.7	5,837.6
Capital WIP	1,115.8	1,129.7	1,229.7	1,329.7
Fixed Assets	7,983.2	7,965.4	7,583.4	7,167.3
Investments	385.0	241.0	241.0	241.0
Goodwill on Consolidation	1,122.6	1,130.4	1,130.4	1,130.4
Other non-Current Assets	114.9	135.6	138.3	141.1
Deferred Tax Assets	386.5	397.9	0.0	0.0
Inventory	2,175.9	2,447.4	2,462.8	2,752.8
Debtors	2,134.4	1,827.1	2,762.5	3,087.8
Other Current Assets	652.7	826.4	842.9	859.8
Cash	356.8	270.3	605.9	876.5
Total Current Assets	5,319.8	5,371.3	6,674.2	7,576.8
Creditors	1,538.4	1,335.7	1,883.3	2,105.1
Provisions	43.6	51.0	52.0	53.0
Other Current Liabilities	678.9	707.6	721.8	736.2
Total Current Liabilities	2,260.9	2,094.3	2,657.1	2,894.3
Net Current Assets	3,058.9	3,277.0	4,017.1	4,682.6
Application of Funds	13,051	13,147	13,110	13,362

Source: Company, ICICI Direct Research

Exhibit 6: Key ratios				
(Year-end March)	FY24	FY25E	FY26E	FY27E
Per share data (₹)				
Reported EPS	0.1	0.6	3.5	5.7
Cash EPS	0.6	0.6	3.5	5.7
BV per share	59.9	59.9	63.3	69.0
Cash per Share	2.7	2.0	4.6	6.6
Dividend per share	0.0	0.0	0.0	0.0
Operating Ratios (%)				
Gross Profit Margins	63.8	65.0	66.1	66.1
EBITDA margins	14.6	14.7	17.3	19.2
PAT Margins	1.0	0.8	4.3	6.3
Cash Conversion Cycle	124	115	115	115
Asset Turnover	0.9	0.9	1.0	1.1
EBITDA conversion Rate	84.0	73.8	73.8	71.9
Return Ratios (%)				
RoE	1.0	0.9	5.5	8.2
RoCE	5.0	5.6	8.1	11.1
RoIC	4.1	5.1	8.4	12.2
Valuation Ratios (x)				
P/E	1,866.7	443.5	72.7	44.6
EV / EBITDA	31.3	27.6	20.2	15.9
EV / Net Sales	4.6	4.1	3.5	3.1
Market Cap / Sales	4.1	3.6	3.1	2.8
Price to Book Value	4.2	4.2	4.0	3.7
Solvency Ratios				
Debt / EBITDA	3.9	3.5	2.3	1.7
Debt / Equity	0.6	0.6	0.5	0.4
Current Ratio	2.2	2.4	2.3	2.3
Quick Ratio				
Inventory days	97	96	85	85
Debtor days	95	72	95	95
Creditor days	69	52	65	65

Source: Company, ICICI Direct Research

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.